Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial
Open Access
- 16 May 2013
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 14 (1) , 143
Abstract
Background: A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm. The risk is highest within the first 6 hours after the initial hemorrhage. Securing the aneurysm within this timeframe is difficult owing to logistical delays. The rate of recurrent bleeding can also be reduced by ultra-early administration of antifibrinolytics, which probably improves functional outcome. The aim of this study is to investigate whether ultra-early and short-term administration of the antifibrinolytic agent tranexamic acid (TXA), as add-on to standard SAH management, leads to better functional outcome. Methods/Design: This is a multicenter, prospective, randomized, open-label trial with blinded endpoint (PROBE) assessment. Adult patients with the diagnosis of non-traumatic SAH, as proven by computed tomography (CT) within 24 hours after the onset of headache, will be randomly assigned to the treatment group or the control group. Patients in the treatment group will receive standard treatment with the addition of a bolus of TXA (1 g intravenously) immediately after randomization, followed by continuous infusion of 1 g per 8 hours until the start of aneurysm treatment, or a maximum of 24 hours after the start of medication. Patients in the control group will receive standard treatment without TXA. The primary outcome measure is favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin Scale (mRS), at 6 months after SAH. Primary outcome will be determined by a trial nurse blinded for treatment allocation. We aim to include 950 patients in 3 years. Discussion: The strengths of this study are: 1. the ultra-early and short-term administration of TXA, resulting in a lower dose as compared to previous studies, which should reduce the risk for delayed cerebral ischemia (DCI), an important risk factor in the long-term treatment with antifibrinolytics; 2. the power calculation is based on functional outcome and calculated with use of recent study results of our own population, supported by data from prominent studies; and 3. the participation of several specialized SAH centers, and their referring hospitals, in the Netherlands with comparative treatment protocols. Trial registration: Nederlands Trial Register (Dutch Trial Registry) number NTR3272Keywords
This publication has 21 references indexed in Scilit:
- European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid HaemorrhageCerebrovascular Diseases, 2013
- Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trialBMJ, 2012
- Guidelines for the Management of Aneurysmal Subarachnoid HemorrhageStroke, 2012
- Outcome After Spontaneous Subarachnoid Hemorrhage Measured With the EQ-5DStroke, 2011
- Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysisActa Neurochirurgica, 2011
- Does Treatment of Ruptured Intracranial Aneurysms Within 24 Hours Improve Clinical Outcome?Stroke, 2011
- Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid HemorrhageStroke, 2008
- Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trendsJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Sentinel Headache and the Risk of Rebleeding After Aneurysmal Subarachnoid HemorrhageStroke, 2006
- Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or ageJournal of Neurosurgery, 2002